“The Kineticos Disruptor Fund is focused on investing with entrepreneur scientists in disruptive platform technologies in areas of large, unmet medical needs,” said Abe Maingi, Partner at Kineticos Disruptor Fund. “We are excited to lead the Series B-1 round for Promaxo as they fit our Fund’s focus perfectly. We look forward to remaining long-term partners with Promaxo.”
The Kineticos Disruptor Fund will focus on large, unmet medical needs in oncology, neurosciences and rare diseases. In oncology, new approaches to solid tumors and “off the shelf” allogeneic cell therapies are immediate priorities. Kineticos will support entrepreneur-scientists and the biotech community through Series A funding.
Kineticos’ Founder and CEO, Shailesh Maingi states: “With the launch of the Kineticos Disruptor Fund, we are able to support the biotech community from concept to commercialization. I am very excited to work with my investment partners Mark Bamforth (Founder, Arranta Bio and previous Founder, Brammer Bio), Derek Hennecke (Founder, Xcelience) and Abe Maingi (VP, Kineticos) and I know of no better way to advance science than through capitalism.”
In addition to supporting existing biotechs, the Kineticos Disruptor Fund will work with technology partners, including leading universities and other research centers. In this venture creation model, Kineticos will in-license technologies and build teams from its extensive community of advisors to advance new platforms.
Kineticos is an award-winning organization supporting Biopharmaceutical and Precision Medicine firms. Launched in 2007, Kineticos initially concentrated on strategy, licensing, and market access support for Precision Medicine firms. In 2012, Kineticos launched its Biopharmaceutical practice. In 2016, Kineticos launched its internal think tank, The Kineticos Research Institute, which includes the Biotech CEO Confidence Index, The Disruptor26 podcast series, white papers, and other relevant content. In 2019, Kineticos was selected as Life Science Consultant of the Year.
In 2020, with the launch of the Kineticos Disruptor Fund, Kineticos recognized the need for a new model to support life science start-ups integrating intelligent funding, biotech expertise, and thoughtful execution. Kineticos has a deep and talented community of advisors to support biotech formation and funding. Ongoing relationships with larger pharmaceutical and biotech companies provide our portfolio companies with numerous opportunities for research collaborations and non-dilutive funding.